Clinical Trials

Clinical Trials

To fulfill our passion for clinical research, Advanced Neurology of Colorado has a research counterpart, Advanced Neurosciences Research, LLC.  Currently, the research team participates in over 15 clinical trials, including those listed below. Following are the clinical trials that we are currently enrolling participants. For more information, please visit http://www.clinicaltrials.gov

Multiple Sclerosis Trials

ENLIGHTEN

A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

https://clinicaltrials.gov/ct2/show/NCT04140305?term=celgene&cond=multiple+sclerosis&draw=2&rank=1

evolutionRMS1
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety

https://clinicaltrials.gov/ct2/show/NCT04338022?term=evobrutinib&cond=multiple+sclerosis&draw=2&rank=1

EXCHANGE

Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study

https://clinicaltrials.gov/ct2/show/NCT03623243?term=exchange&cond=multiple+sclerosis&draw=2&rank=3

GEMINI 2
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis

https://clinicaltrials.gov/ct2/show/NCT04410991?term=EFC16034&cond=multiple+sclerosis&draw=2&rank=1

PERSEUS
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis

https://clinicaltrials.gov/ct2/show/NCT04458051?term=EFC16035&cond=multiple+sclerosis&draw=2&rank=1

HERCULES
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis

https://clinicaltrials.gov/ct2/show/NCT04411641?term=EFC16645&cond=multiple+sclerosis&draw=2&rank=1

CLICK-MS
Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)

https://clinicaltrials.gov/ct2/show/NCT03933215?term=mavenclad&cond=multiple+sclerosis&draw=2&rank=6

MASTER-2
Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)

https://clinicaltrials.gov/ct2/show/NCT03933202?term=mavenclad&cond=multiple+sclerosis&draw=2&rank=7

COMING SOON:

A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

https://clinicaltrials.gov/ct2/show/NCT04544436?term=BN42082&cond=multiple+sclerosis&draw=2&rank=1

 


Migraine Trials

PRODROME
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome

COMING SOON:

All of our trials are currently enrolling, please continue to check back for upcoming trials


Myasthenia Gravis Trials

ALXN1210-MG-306
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

https://clinicaltrials.gov/ct2/show/NCT03920293?term=ravulizumab&draw=2&rank=4

COMING SOON:

All of our trials are currently enrolling, please continue to check back for upcoming trials